FILING ANALYSIS · THURSDAY, NOVEMBER 5
TENAX THERAPEUTICS, INC. TENX — 8-K: Results of Operations and Financial Condition
neutral
Tenax Therapeutics reported third quarter financial results and provided a corporate update, including the completion of statistical analyses of the LEVEL trial, which identified a predictive enrichment strategy being applied in the amended LEVEL-2 protocol, and a granted Type C meeting with the FDA to discuss levosimendan development in PH-HFpEF. The company's focus on enrolling a more symptomati
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →